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ABSTRACT
Introduction: The goal of chronic hepatitis C
(CHC) treatment is to achieve a sustained
virologic response (SVR). The new generation
of direct-acting antivirals (DAAs) offers
90–100% SVR rates. However, access to these
treatments is generally limited to patients with
advanced liver disease. The aim of this review is
to provide an overview of the clinical and
economic benefits of achieving SVR and to
better understand the full value of CHC
treatment in all stages of liver disease.
Methods: A comprehensive literature review
was performed using the PubMed, Embase,
and Cochrane library databases to identify
articles examining the clinical, economic, and
quality of life benefits associated with SVR.
Articles were limited to those published in
English language from January 2006 through
January 2016. Inclusion criteria were (1)
patients with CHC, (2) retrospective and
prospective studies, (3) reporting of mortality,
liver morbidity, extrahepatic manifestations
(EHMs), and economic outcomes and, (4)
availability of an abstract or full-text
publication.
Results: Overall this review identified 354
studies involving more than 500,000 CHC
patients worldwide. Evidence from 38 studies
(n = 73,861) shows a significant mortality
benefit of achieving SVR in patients with all
stages of fibrosis. Long-term studies with
follow-up of 5–12 years suggest that,
particularly among non-cirrhotic patients,
there is a significant decrease in mortality in
SVR versus non-SVR groups. Ninety-nine studies
conducted in 235,891 CHC patients in all stages
of fibrosis show that SVR reduces liver-related
mortality, incidence of hepatocellular
carcinoma (HCC), and decompensation. A
total of 233 studies show that chronic HCV
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infection is associated with several serious
EHMs, some of which can have high
mortality. Evidence from four modeling
studies shows that delaying treatment to CHC
patient populations could significantly increase
mortality, morbidity, and medical costs.
Conclusions: There is a robust body of evidence
demonstrating diverse sources of value from
achieving SVR in all stages of liver disease.
While access to treatment is generally limited to
late-stage patients, less restrictive treatment
strategies that target HCV eradication have the
potential to abate the burdens of mortality, liver
morbidity and extrahepatic manifestations, and
the associated healthcare costs.
Keywords: Clinical/economic burden;
Extrahepatic manifestations; Hepatitis C virus;
Liver mortality/morbidity; Sustained virologic
response
INTRODUCTION
Hepatitis C virus (HCV) infection represents a
significant public health burden, with at least
150 million individuals chronically infected
worldwide [1]. The goal of chronic hepatitis C
(CHC) treatment is to achieve a sustained
virologic response (SVR), which represents
HCV clearance to undetectable levels and is
considered a ‘‘virologic cure’’ [2]. Until 2011 the
only available treatment was based on the
combination of pegylated interferon and
ribavirin (PEG/RBV). However, in genotypes 1
and 4 the rates of SVR were less than 50%. In
2011 protease inhibitors in combination with
PEG/RBV were approved for treatment of
genotype 1. While the SVR rates improved to
75–80%, those treatments were associated with
high toxicity and poor safety profile [3]. Novel,
interferon (INF)-free direct-acting antiviral
(DAA) therapies have demonstrated SVR rates
of 90–100% and high tolerability in clinical
trials [3, 4]. However, access to these agents is
generally limited to patients with late-stage
disease [5–7]. As such, it is important to offer a
perspective on the consequences of this missed
treatment opportunity in a broad range of
patients.
This literature review was conducted with
the objective of providing a comprehensive
review of evidence demonstrating the value of
achieving SVR at all stages of liver disease,
focusing on four topics: (1) all-cause and
liver-related mortality, (2) liver-related
morbidity, (3) extrahepatic manifestations
(EHMs), and (4) economic impact. The
underlying hypothesis is that if HCV affects
liver morbidity and EHMs, it should also impact
liver-related and all-cause mortality and,
ultimately, increase the economic burden of
healthcare spending.
METHODS
The feasibility of conducting an original global
systematic review was assessed using criteria
from the preferred reporting items for
systematic reviews and meta-analyses
(PRISMA) [8] for the last 10 years. Preliminary
searches revealed more than 400 references that
potentially met our inclusion criteria (described
below). Within these publications, search was
further limited to review articles and
meta-analyses published between 2006 and
January 2016 as well as updates since the last
publication date of a review or meta-analysis.
However, for the section on EHMs there were
no systematic reviews that addressed a
comprehensive list of EHMs. Hence, we pooled
the references from two recent review articles
[9, 10] and conducted additional searches for
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any recent publications related to the EHMs
associated with CHC treatment.
Searches were conducted using the Embase,
PubMed, and Cochrane library databases, as
well as a review of conference abstracts and
general web searches. Inclusion criteria were (1)
patients with CHC (excluding special
populations such as liver transplant recipients,
HIV-HCV co-infected patients, and recurrent or
acute HCV cases), (2) retrospective and
prospective studies (excluding case report
studies), (3) reporting of mortality, liver
morbidity, EHM, and economic outcomes, and
(4) availability of an abstract or full text from
the study publication.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
Our search results are summarized in Fig. 1. For
the first topic we identified a 2015 meta-analysis
on the survival benefit of SVR. This paper
evaluated 31 studies published between 1990
and November 2014 [11]. We then conducted
an additional search to include all articles
published between December 2014 and
January 2016. This identified seven new
studies on the impact of SVR on survival or
mortality (Table S1).
For the topic on liver morbidity, our search
identified one systematic review from 2011 of
67 studies [12] and one meta-analysis from 2010
of 26 studies [13]. During our search for
publications from 2010 to January 2016, we
identified six new studies (Table S2).
Our literature search did not find systematic
reviews or meta-analyses that addressed all
major types of extrahepatic manifestations
identified in the literature. However, we
identified and summarized one meta-analysis
on the prevalence of a few select EHMs [14], and
located multiple commentary-style reviews,
which collectively summarized between 150
and 250 studies. We also leveraged two recent
reviews [9, 10] and pooled their references into
one database, with a total of 350 references.
This database was manually screened and
prioritized for high-quality evidence based on
study type (prospective versus retrospective)
and size (Table S4). We identified seven
epidemiological studies on several types of
EHMs and 12 publications that studied the
impact of SVR on EHMs (Table S5).
Lastly, on the topic of economic value, our
search identified four studies on different
strategies for treating HCV. We came across
one systematic review on the methodology of
cost-effectiveness analysis of antiviral therapy.
We leveraged and updated that review to
provide a summary of cost-effectiveness
publications (Table S6). Overall, this review
summarizes results from 354 studies
conducted with more than 500,000 CHC
patients worldwide. The studies in each
section are summarized in a decreasing order
of strength of evidence, meta-analysis followed
by prospective and retrospective studies.
Survival Benefit of SVR
Our review shows that 38 studies with a total of
73,861 HCV patients have demonstrated
significant improvement in long-term survival
among patients who achieve an SVR versus
those who do not. While this benefit is
significant in all HCV patients, cirrhotic or
non-cirrhotic, patients who achieve SVR at
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earlier disease stages have the lowest mortality
risk.
A meta-analysis of 31 studies (n = 33,360 and
median follow-up of 5.4 years) conducted
between 2001 and 2014 found that there is a
significant survival benefit of achieving an SVR
compared with unsuccessful treatment in a
broad range of populations infected with HCV.
The general population group (monoinfected
patients at all disease stages) included 17 studies
(n = 28,451), with approximately 33% of the
patients with F1 stage of liver fibrosis. The
cirrhotic patient group included nine studies
(n = 2886) with 100% of the patients in F3 stage
or higher. In this meta-analysis, the adjusted
hazard ratio (aHR) of all-cause mortality for
HCV patients achieving SVR vs non-SVR was
0.50 (95% CI 0.37–0.67) in the general
population and 0.26 (95% CI 0.18–0.74) in the
cirrhotic group. The pooled 5-year mortality
rates were significantly lower for patients
achieving SVR compared with non-SVR in all
three populations. The authors concluded that
after adjusting for potential confounding
factors, an SVR was associated with
approximately a 50% and 74% decreased risk
of all-cause mortality compared with not
achieving an SVR in the general and cirrhotic
populations, respectively [11].
A 12-year follow-up study was conducted
with 24,968 HCV patients from the Kaiser
Permanente integrated healthcare system in
the USA. In this study, mortality was markedly
higher in patients with cirrhosis who did not
achieve SVR (23.7%) vs cirrhotics who did
achieve SVR (8.1%), nearly a threefold increase
(p\0.0001). Among non-cirrhotics, there was a
2.5-fold increase in mortality in those who did
Search for latest available meta-analysis or systematic reviews on: 
(1) Effect of SVR on survival 
(2) Liver-related morbidity 
(3) Extrahepatic manifestations (EHMs) 
(4) Economic impact of different treatment strategies  
Simmons et al 2015 
Systematic Review & 
Meta-Analysis 
(n=31 studies) 




Singal et al 2010  
Meta-Analysis 
(n=26 studies) 
Younossi et al 2015 Meta-
Analysis (n=69 studies) 
Cacoub et al 2014 Review 
(n=182 references) 
Negro et al 2015 Review 
(n=156 references) 
Chattwall et al 2015 
Systematic Review 
(n=36 studies) 
Search for recent publications on all four topics using Embase, Pubmed, Medline, Cochrane and Conference Abstracts 
 
7 new studies on  
survival benefit  
of SVR (2014–2016) 
4 new studies on  
liver effects and impact 
of SVR (2011–2016) 
• 7 studies on prevalence of all EHMs 
• 11 studies on specific EHMs 
• 12 studies on impact of SVR on EHMs 
• 1 meta-analysis on diabetes (n=34 studies) 
• 1 meta-analysis on insulin resistance (n=14 
studies) 
• 1 meta-analysis on NHL EHM (n=15 studies) 
• 1 meta analysis on depression (n=12 studies) 









Total of 354 studies summarized 
Fig. 1 Summary of search results
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not achieve SVR (5.3%) compared to those who
achieved SVR (2.1%). Importantly, patients who
achieved SVR with cirrhosis had nearly four
times higher mortality risk than patients who
achieved SVR without cirrhosis [15].
Another large observational study with 9143
patients (moderate to advanced fibrosis) with a
median follow-up of 6.4 years in four US health
systems found that successful treatment leading
to SVR significantly reduced mortality (aHR
0.40, 95% CI 0.28–0.56) compared to no
treatment [16].
In France access to antiviral therapy is
generally limited only to moderate-to-advanced
fibrosis stage patients. To highlight the high
incidence of mortality and morbidity in early
Metavir fibrosis stage patients (F0 and F1)
Jez´equel et al. conducted a follow-up study with
820 patients. After a median follow-up of
4.6 years, an increased fibrosis stage to F3 or F4
was observed in 15.3% of F0–F1 patients and 48%
of F2 patients. In addition, 46.7% of F3 patients
progressed to F4. After a median follow-up of
11.9 years, 248 patients died (16.7%), more
frequently in fibrosis stages F2–F4 (24.4%) than
in F0–F1 (11.5%) (p\0.05). Median survival at 5,
10, and 15 years after the first liver biopsy was
97.4, 93.1, and 87% in F0–F1 patients and 93.2,
83.4, and 65.4% in F2–F4 patients. Survival was
higher in treated patients with SVR than in
untreated patients or treatment failures
regardless of fibrosis stage (p\0.01) [17, 18].
Propensity score analysis of 2743 Japanese
patients followed for more than 10 years (range
10.5–14.2 years) showed that the eradication of
HCV (defined as achieving SVR) significantly
reduced all-cause mortality (HR 0.265; 95% CI
0.06–0.38), including non-liver-related
mortality (HR 0.439; 95% CI 0.23–0.83),
compared to no treatment [19]. Another
Japanese study of 1125 elderly HCV patients
used propensity-score-adjusted Cox
proportional analysis to show that achieving
an SVR significantly reduced total mortality risk
(HR 0.077, CI 0.011–0.550; p = 0.011),
compared to no SVR or no treatment [20].
A retrospective analysis of 427 French HCV
patients with advanced liver disease found that
the risk of death or liver transplantation was
significantly lower in SVR than in non-SVR
patients and in non-SVR than in untreated
patients (hazard ratios, 0.35 and 0.51,
respectively; p\0.05), suggesting that even
unsuccessful treatment may convey survival
benefits [21]. In a long-term retrospective
study of 714 Austrian HCV patients with
advanced liver disease, the 5- and 10-year
mortality rates were 1.8% and 2.7% in the SVR
group and 8.6% and 19.1% among non-SVR
patients, respectively (p\0.001) [22].
Liver-Related Morbidity
According to the National Institute of Health
Consensus, the most important sequelae of
chronic HCV infection are progressive liver
fibrosis leading to cirrhosis (compensated-CC
or decompensated-DCC), end-stage liver
disease, and hepatocellular carcinoma (HCC)
[23]. In our review we found one systematic
review of 67 studies, one meta-analysis of 26
studies, and six recent studies showing strong
evidence for high burden of liver-related
complications in CHC patients in all stages of
fibrosis. These publications cumulatively
provide long-term follow-up evidence from
235,891 CHC patients.
A systematic review of 67 studies
(n = 17,025) published during 1991 and 2011
worldwide found that SVR reduced liver-related
mortality among patients with CHC (3.3- to
25-fold), the incidence of HCC (1.7- to 4.2-fold),
and hepatic decompensation (2.7- to 17.4-fold).
The authors concluded that the benefits were
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seen in patients with all stages of liver fibrosis,
and the effects were significant even in
advanced fibrosis stages [12].
A meta-analysis of 26 studies (n = 15,621)
published during 1990 and 2008 found high
rates of liver-related mortality (2.73% per year;
95% CI 1.38–4.080), HCC (3.22% per year, 95%
CI 2.02–4.42), and hepatic decompensation
(2.92% per year; 95% CI 1.61–4.22) among
patients with advanced fibrosis who failed
treatment. Patients with SVR are significantly
less likely than patients who experienced
treatment failure to develop liver-related
mortality (relative risk [RR] 0.23; 95% CI
0.10–0.52), HCC (RR 0.21; 95% CI 0.16–0.27),
or hepatic decompensation (RR 0.16; 95% CI
0.04–0.59). Among studies of patients with
varying levels of fibrosis, the annual rates of
decompensated cirrhosis, HCC, and/or
liver-related mortality vary from 0.56 to
1.39%. This meta-analysis included 20 studies
with patients all stages of fibrosis and five
studies with patients in F3 or F4 fibrosis [13].
In a French prospective cohort study of 1323
HCV patients with compensated cirrhosis
treated with DAAs, there was a three- to
five-fold reduction in critical events,
liver-related or not, among patients achieving
SVR, which led to improved overall and
liver-related survival. Furthermore, SVR was an
independent factor associated with a decreased
incidence of HCC (5 years cumulative
incidence: 3.3% vs. 21.8%, HR 0.21
[0.13–0.36], p\0.001) and hepatic
decompensation (5 years cumulative
incidence: 4.2% vs. 24.0%, HR 0.17
[0.10–0.27], p\0.001) [24].
In a long-term prospective study of up to
23 years with 194 cirrhotic Italian HCV
patients, the rate of HCC was higher in
patients without SVR compared to those with
SVR: 2.7/100 person-years (95% CI 2.1–3.5) and
1.4/100 person-years (95% CI 0.7–2.7),
respectively [p = 0.02, HR (95% CI) 0.42
(0.20–0.89)]. Using multivariate analysis the
authors also found that SVR was not
associated with risk reduction of HCC
development if cirrhosis has already occurred.
On the basis of these results, the authors of this
study suggested that effective antiviral
treatment should be recommended at early
disease stages [25].
In a long-term prospective study with 351
HCV patients in Sweden (most patients were
treated with PEG/RBV), the incidences of HCC,
any liver complication, liver-related death, and
overall death per 100 person-years were
significantly lower in the time lived with SVR
(1.0, 0.9, 0.7, and 1.9), compared to the time
lived treated but without SVR (2.3, 3.2, 3.0, and
4.1) and the time lived without treatment (4.0,
4.9, 4.5, and 5.1) [26]. This supports the notion
that CHC treatment mitigates the risk of liver
morbidity, even when it is unsuccessful.
Tada et al.’s Japanese study (n = 2743)
showed that the eradication of HCV (defined
as achieving SVR) reduced the incidence of HCC
(HR 0.275; 95% CI 0.156–0.448) [19]. Another
Japanese study by Kobayashi et al. (n = 1125)
showed that achieving an SVR significantly
reduced HCC risk (HR 0.118, CI 0.029–0.476;
p = 0.003), compared to no SVR or no treatment
[20].
A large retrospective database study of US
Veteran Affairs patients (n = 187,860)
showed that initiating treatment before
Fibrosis-4 score (FIB4) [1.00 reduced
morbidity by 41% and death by 36% [27].
Similar results were observed in an insurance
database study in Turkey showing that
mortality (2.27% vs. 5.31%; p\0.001) and
HCC rates (0.69% vs. 1.96%; p\0.001) were
lower for treated patients compared to
untreated patients [28].
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Extrahepatic Manifestations (EHMs)
In addition to liver-related morbidity, chronic
HCV infection is associated with changes in
organ systems outside the liver, including
metabolic, cardiovascular, and neurological
systems, and with autoimmune and
immune-mediated conditions such as mixed
cryoglobulinemia (MC), thyroid disease, and
glomerulonephritis. According to a recent
review up to 74% of CHC patients suffer from
EHMs [10]. There is a significant amount of
evidence on prevalence and burden of EHMs in
CHC. Recent reviews have included summaries
from 150 to 250 studies. In this review we
provide an overall summary from 233 studies
on the epidemiology and value of SVR for
reducing the risk of EHMs.
Studies Estimating Broad Prevalence
of EHMs
A recent meta-analysis of 69 studies estimated
the overall burden of seven EHMs due to HCV
(Table S3). In this analysis the pooled prevalence
estimate of MC (n = 14 studies) was 32% in the
HCV group (95% CI 21–43%) and 3% (95% CI
0–8%) in the non-HCV group (n = 3 studies). The
pooled prevalence of diabetes mellitus (DM)
(n = 16 studies) among HCV patients was 15%
(95% CI 13–18%) compared to 10% (95% CI
4–15%) in the non-HCV population. The pooled
odds ratio (OR) of developing chronic kidney
disease/end-stage renal disease (CKD/ESRD) in
patients with HCV compared to the non-HCV
group (n = 11 studies) was 1.29 (95% CI
1.13–1.45). The risk of lymphoma was 64%
higher (OR 1.64; 95% CI 1.18–2.11) in patients
with HCV compared to the non-HCV
population. The pooled prevalence estimate of
lichen planus among HCV (n = 11 studies) was
2.1% (95% CI 1.1–3.1%) while the prevalence in
non-HCV (n = 3 studies) was 1.4% (95% CI
0–3.4%). The pooled prevalence of Sjo¨gren’s
syndrome (n = 6 studies) was 1.11% (95% CI
0.17–0.53%) compared to 0.11% (95% CI
0.09–0.13%) in the non-HCV group (n = 1
study). The pooled prevalence of porphyria
cutanea tarda (PCT) among HCV patients
(n = 5) was 0.7% (95% CI 0.2–1.1%) whereas
the prevalence in the non-HCV group (n = 1
study) was 0.06% (95% CI 0.05–0.07) [14].
Globally, a relatively significant prevalence of
EHMs has been found in CHC patients in five
retrospective studies conducted in Italy
(n = 440), Poland (n = 340), China (n = 297),
Romania (n = 162), and Turkey (n = 62) [29–33].
Studies on Specific EHMs
Mixed Cryoglobulinemia (MC)
Cacoub et al. suggests that the overall 5-year
survival rate after the diagnosis of vasculitis
ranges from 90 to 50%, in case of renal
involvement [10]. In our review we found five
studies with a total of 810 CHC patients which
also show that HCV-related MC can lead to high
mortality in some patients [34–38]. A study
from Spain (n = 279) found that HCV-related
cryoglobulinemia may result in progressive
(renal involvement) or acute (pulmonary
hemorrhage, gastrointestinal ischemia, central
nervous system involvement) life-threatening
organ damage. During mean follow-up of
14 months the mortality rate from these
manifestations in the study group was
between 20% and 80% [37]. In a long-term
efficacy study in France (n = 72), it was shown
that an early virologic response (odds ratio 3.53,
95% confidence interval [CI] 1.18–10.59) was
independently associated with a complete
clinical response of MC [38].
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Non-Hodgkin’s Lymphoma (NHL)
A large meta-analysis of 15 case–control studies
and three prospective studies with a total
number of 12,235 CHC patients estimated the
pooled RR of NHL among HCV-positive
individuals as 2.5 (95% CI 2.1–3.0) [39].
Another meta-analysis conducted primarily
with Italian and Japanese studies including
4049 NHL patients and 1813,480 controls also
found a strong positive association between
anti-HCV seropositive test subjects and risk of
NHL (OR for NHL was 5.70, 95% CI 4.09–7.96,
p\0.001) [40].
Type II Diabetes Mellitus (DM)
In a meta-analysis of 34 studies the pooled
estimate indicated significant DM risk in
HCV-infected cases in comparison to
non-infected controls in both retrospective
(ORadjusted = 1.68, 95% CI 1.15–2.20) and
prospective studies (HRadjusted = 1.67, 95% CI
1.28–2.06) [41].
Insulin Resistance (IR)
In a retrospective study of the US National
Health and Nutrition Examination Survey
(NHANES) (n = 173) CHC was independently
associated with the presence of IR [OR (95% CI)
2.06 (1.19–3.57)], DM [OR 2.31 (1.18–4.54)],
and hypertension [OR 2.06 (1.30–3.24)] [42].
Recently, the evidence of IR in HCV patients
was confirmed by a meta-analysis of 14 studies,
involving 3659 patients. This analysis showed
that the RR of IR among HCV subjects with
advanced hepatic fibrosis (F3 and F4) was 1.63
[95% confidence interval (CI) 1.34–2.01],
compared to patients with F0–F2 fibrosis [43].
In a recent review, Negro et al. suggested that
the most compelling evidence that HCV causes
IR is the observation that curing HCV with
antiviral therapy results in reduced levels of IR,
citing a Japanese study of 89 patients, which
showed that clearance of HCV improves IR,
beta-cell function, and hepatic IRS1/2
expression [9, 44].
Renal Insufficiency
In a retrospective study of patients in the US
Veteran Affairs healthcare system (n = 1928 HCV
antibody positive and n = 23,854 HCV antibody
negative), after adjustment for age, race, gender,
diabetes, and hypertension, HCV-positive
veterans had a 40% higher odds for renal
insufficiency (odds ratio 1.40; 95% CI 1.11–1.76)
as compared with HCV-negative veterans [45].
A large-scale community study (n = 54,966)
on the effect of viral hepatitis (HCV or HBV) on
nephropathy in Taiwan found that HCV
infection alone (OR 1.26; 95% CI 1.17–1.38)
was an independent risk factor for CKD, but not
HBV infection alone or HBV/HCV coinfection
[46].
Cardiovascular Disorders
A meta-analysis of six studies showed a strong
link between HCV and risk of stroke, with
22,171 HCV-infected individuals and 87,418
controls, and an estimated pooled OR of 1.58
(0.86, 2.30) [47]. Similarly, high risk of stroke
was observed in a large retrospective database
study in Taiwan (n = 4084 HCV and n = 16,376
controls), with a cumulative risk of stroke for
people with and without HCV of 2.5% and
1.9%, respectively (p\0.0001). Compared to
people without HCV, the adjusted HR of stroke
was 1.27 (95% CI 1.14–1.41) for people with
HCV [48].
A strong link between HCV and coronary
artery disease (CAD) was observed in a large
database study of US Veteran Affairs patients
(n = 82,083 HCV-infected and n = 89,582
HCV-uninfected). The study showed that HCV
infection was associated with a higher risk of
CAD (HR 1.25; 95% CI 1.20–1.30) [49].
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Depression
A meta-analysis including 12 studies
(n = 130,039 in 5 cross-sectional, 3
longitudinal, 3 prospective, and 1 retrospective
chart review) estimated the pooled prevalence
of depression among HCV patients at 24.5%
(95% CI 14.1–34.9%) [50]. This rate of
depression is almost 20% higher than the rate
of depression in the general population.
Quality of Life
A systematic review of 73 studies (n = 130,039)
concluded that HCV has a negative impact on
health-related quality of life (HRQL, 61 studies),
fatigue (20 studies), and work productivity (3
studies) [51].
Studies on Value of Antiviral Therapy
in Patients with HCV-Related EHMs
In our review we found 15 studies (n = 12,974),
which have demonstrated value of antiviral
therapy in lowering the burden of EHMs in
CHC patients (Table S4). A prospective study of
424 CHC patients in Italy showed that in the
majority of patients (36 patients, 57%) all
mixed cryoglobulinemia syndrome (MCS)
symptoms persistently disappeared after
achieving SVR [52]. In a retrospective study of
Japanese patients (n = 3209) the HR of
lymphomagenesis in 1048 patients with SVR
was significantly lower than in patients with
persistent infection (hazard ratio 0.13; p\0.05),
demonstrating that SVR protects against the
development of malignant lymphoma in
patients with chronic HCV [53]. Another
Japanese study of 2842 patients showed that
SVR caused a two-thirds reduction in the risk of
type 2 DM development in HCV-positive
patients treated with antiviral therapy [54]. In
a US randomized study of 1121 CHC patients,
SVR was associated with improvement at
follow-up on all Short-Form Health Survey
(SF-36) and Functional Systems Scores (FSS)
components [55]. SF-36 is a validated and
commonly used questionnaire for assessing
HRQOL; it has 36 measures with 8 subscales
including physical functioning and vitality.
Economic Value of Treatment
The cost-effectiveness of antiviral therapy
(including DAAs) has been demonstrated in 35
published studies, which include 30 Markov
models, 2 micro simulations, 1 discrete event
simulation, and 1 hybrid model (Table S6).
Fifteen of the 35 analyses were conducted in
the USA, 5 in Italy, 4 in the UK, and 3 in Spain.
Cost-effectiveness of treatment for naı¨ve and
non-cirrhotic patients was specifically analyzed
in 11 and 4 analyses, respectively. We
conducted additional search for any
cost-effectiveness analyses, economic impact,
or database studies examining the impact of
delaying or deferring antiviral treatment.
Overall, these modeling analyses show that
newer-generation treatments (e.g., INF-free
DAAs) are more cost-effective than older (e.g.,
INF-based) regimens, and early treatment is
cost-effective compared to treatment at late
CHC stages.
A US decision analytic model analyzed the
cost-effectiveness of six novel DAAs at different
stages of fibrosis. Their analysis shows that
treatment with DAA as early as stage F1 is
cost-effective (incremental cost-effectiveness
ratios [ICERs] of US$50,000–150,000 per
quality-adjusted life year [QALY] gained) and
less than US$50,000 per QALY gained when
treatment is initiated at stage F2 vs stage F3 [56].
A Markov modeling analysis in the USA
showed that treatment with a DAA at F2
rather than F3–F4 is projected to have even
greater efficacy, decreasing the average number
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of cases of DCC by 63.3%, HCC by 89.0%, liver
transplants by 83.3%, and HCV-related deaths
by 84.5% [57]. Similar results were observed for
a model in the Spanish setting, which
demonstrated that, compared to delayed
administration of therapy at F4, initiating DAA
treatment at early disease stages (F2–F3) reduced
the incidence of new cases of liver-disease
complications and was associated with cost
savings for the Spanish National Health
System in previously untreated genotype 1
HCV patients [58].
A natural history Markov model showed that
initiation of treatment with DAAs at later stages
of fibrosis resulted in greater average annual
lifetime post-treatment costs and fewer life
years compared to treatment initiation at
earlier fibrosis stages; in particular,
treatment-naı¨ve patients treated in F0 stage
had average annual medical costs of US$314
(US$228 discounted), whereas patients treated
in F4 stage had over 10-fold greater annual
medical costs (US$3187) [59].
A disease progression model estimated the
cost-effectiveness of using PEG/RBV and/or PEG/
RBV with protease inhibitors in 16 countries and
showed that treatments with higher efficacy and
increased uptake are needed to control HCV
burden [60]. Bruggmann et al. developed a
follow-up model to assess the impact of
delaying treatment scenarios in Switzerland.
The model showed that a 2-year delay in
treatment could reduce the impact of disease
burden control efforts by 10%, while a 5-year
delay could reduce the impact by 30% [61]. The
authors concluded that a substantial reduction
in disease burden could be achieved by means of
both higher efficacy drugs and increased
treatment uptake, underscoring the importance
of comprehensive treatment with INF-free DAA
therapies [62].
DISCUSSION
In our review of the literature we found a large
body of evidence demonstrating diverse sources
of value for CHC patients achieving SVR in all
stages of liver disease. Overall, this review
summarizes results from 354 studies
conducted in more than 500,000 patients. The
summarized evidence confirms our hypothesis
that HCV affects liver morbidity and EHMs,
which leads to increased liver-related and
all-cause mortality and high economic burden.
The evidence also strongly demonstrates that
achievement of SVR can increase survival,
reduce liver and extrahepatic morbidity, and
lower long-term costs. Even unsuccessful CHC
treatment appears to have a protective effect
against mortality and liver morbidity.
Furthermore, treatment with newer-generation
regimens (e.g., INF-free DAAs) is generally
cost-effective compared to older (e.g.,
INF-based) regimens. Similarly, treatment in
early fibrosis stages is cost-effective relative to
late treatment.
Most notable is the evidence from 38 studies
showing (n = 73,861) significant mortality
benefit of SVR in patients with all stages of
fibrosis. Ninety-nine studies conducted in
235,891 CHC patients in all stages of fibrosis
have shown that SVR reduces liver-related
mortality (3.3- to 25-fold), incidence of HCC
(1.7- to 4.2-fold), and hepatic decompensation
(2.7- to 17.4-fold) [12, 13]. Evidence from
modeling studies confirms these results by
showing that delaying treatment could
significantly increase mortality, morbidity, and
medical costs. Additionally, there are more than
200 studies which have shown that chronic
HCV infection is associated with several serious
EHMs, some of which can have high mortality
[9, 10].
500 Infect Dis Ther (2016) 5:491–508
Despite a compelling and robust body of
clinical and economic evidence, current access
to DAAs has been limited largely to patients
with advanced liver disease. This restriction on
access is either due to a perception that patients
in early stages of fibrosis can wait and/or due to
the short-term costs of treating patients in all
fibrosis stages. However, as this review shows,
there is compelling clinical and economic
evidence that treatment for patients in early
and all stages of fibrosis improves survival,
reduces liver-related and extrahepatic
morbidity, and is cost-effective.
In spite of numerous challenges, some
countries or regions have implemented
comprehensive treatment strategies for CHC.
In 2013, when INF-free DAAs were licensed,
Georgia engaged partners to develop a national
HCV prevention and control plan targeting the
elimination of HCV transmission and disease
[63]. Similarly, the Hepatitis Prevention,
Control, and Elimination (HPCE) Program was
officially launched in September 2014 to
radically change the current state of viral
hepatitis in Mongolia and significantly reduce
the disproportionate and sustained burden of
liver cirrhosis, liver cancer, and mortality [64].
In Egypt, the government has launched a
comprehensive HCV treatment program with a
goal to treat 300,000 people a year (WHO 2015).
In these exemplary cases, a strong healthcare
infrastructure and political will are crucial to
battle HCV by implementing effective screening
and treatment programs [65]. In Australia, the
federal government has announced that it will
subsidize new breakthrough HCV treatments to
cure all patients [66]. The implementation and
outcomes of these programs should be closely
monitored as they could provide valuable
real-world policy lessons for other regions.
Recently, the French government announced
plans to provide universal access to new HCV
medications [67].
The demonstrated value of achieving SVR
underscores the importance of comprehensive
treatment strategies targeting all stages of liver
disease and based on the most effective and
tolerable class of DAA regimens. It should be
further noted that the majority of the studies
summarized here were conducted with
INF-based antivirals which had relatively low
cure rates and high toxicity. The new
generation of DAAs offer 90–100% cure rates
and have a significantly better safety profile,
making the case even stronger to offer these
treatment options to patients in all stages of
liver disease [3].
There are some limitations of our review. As
a result of the broad scope of the topic and
robust body of evidence it was not possible to
conduct a full systematic review. However, to
provide a summary on relevant topics we
leveraged the highest-quality evidence such as
meta-analyses and systematic reviews.
Additionally, our review focused only on the
treatment for HCV. There are other areas such
as disease awareness, diagnosis, and monitoring
which also need policy interventions for
developing successful and comprehensive HCV
eradication plans.
Though this review demonstrates the need
and value of treatment for all HCV patients,
expansion of access should be considered
within comprehensive plans aimed at the
prevention, control, and eradication of
HCV, taking into account the budgetary
impact and health system infrastructure of
each country. The design and implementation
of healthcare solutions for effective CHC
control remains a crucial topic of analysis in
order to capture the full value of effective and
comprehensive treatment opportunities.
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